Other News To Note
Tuesday, June 7, 2011
Versartis Inc., of Mountain View, Calif., reported long-term preclinical safety data showing that VRS-317, its once-monthly version of recombinant human growth hormone, was well tolerated when dosed in monkeys every two weeks for three months. Data also further supported once-monthly treatment in humans. GLP toxicology studies in monkeys for both acute (four weeks) and long-term (13 weeks) exposure at doses of up to 25 mg/kg showed no observed adverse events, and no lipoatrophy or anti-XTEN antibodies were detected.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.